Table 3.

Molecular determinants of the therapeutic response

Case no.EGFR Ampl/vIII*p53p-AktPTEN§DC101 responseCetuximab response
1+/+4%++
2+/−>93%+
3+/+<1%++
4+/+<1%+++
5+/+16%+++
6−/−58%++
7−/−55%+
8−/−3%+
9−/−<1%+
  • Abbreviations: Ampl, EGFR amplification in the original tumor; vIII, expression of EGFRvIII in the original tumor.

  • * +, present; −, absent.

  • Percentage of p53 immunoreactive cells determined on tumor paraffin sections.

  • +, tumors were either focally or diffusely immunoreactive for p-Akt; −, tumors were negative for p-Akt.

  • § +, immunoreactivity of tumor cells was equal to or stronger than that of vascular endothelium; −, immunoreactivity of tumor cells was diminished or absent in at least 25% of the tumor cells relative to endothelium.

  • −, no significant tumor cell reduction by DC101 compared with vehicle i.p. controls at 36 pooled landmark points.

  • +, significant tumor cell reduction by cetuximab compared with vehicle i.c. controls at 36 pooled landmark points; −, no significant response.